Thai Union, S2G Ventures among new investors in aquaculture biotech firm ViAqua

Biotech firm ViAqua aims to improve shrimp health and combat disease with its RNA-particle platform.

Biotechnology company ViAqua Therapeutics announced that its recently-completed 4.3 million (EUR 3.5 million) funding round will be used to support the commercialization of its first product dedicated to improving shrimp health …

Photo courtesy of ViAqua Therapeutics


SeafoodSource Premium

Become a Premium member to unlock the rest of this article.

Become a member ›Already a member? Log In ›

Subscribe

Want seafood news sent to your inbox?

You may unsubscribe from our mailing list at any time. Diversified Communications | 121 Free Street, Portland, ME 04101 | +1 207-842-5500
None